ABBV · News · 20260910N
Immunology Product Demand and Expansion
AbbVie Inc. · 2026-09-10 · Importance 60 · Surprise 24 · In source text
AbbVie’s immunology franchise is being driven by Skyrizi and Rinvoq, which a third-party report described as generating more than half of AbbVie’s revenue in the first half of 2026. The products have offset revenue erosion from Humira biosimilars, indicating continued demand and successful franchise transition. Combined Skyrizi and Rinvoq sales are expected to exceed $31 billion in 2026, while AbbVie continues expanding the immunology pipeline through internal research, acquisitions, and collaborations amid competition from other large pharmaceutical companies.
Key facts
- AbbVie anticipates combined Skyrizi and Rinvoq sales to surpass $31 billion in 2026. source
- AbbVie's immunology franchise, driven by Skyrizi and Rinvoq, had sales exceeding half of the company's total revenue in the first half of 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie anticipates combined Skyrizi and Rinvoq sales to surpass $31 billion in 2026. |
| revenue | positive | realized | — | AbbVie's immunology franchise, driven by Skyrizi and Rinvoq, had sales exceeding half of the company's total revenue in the first half of… |